May 8 |
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
|
May 8 |
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
|
May 3 |
Compass Pathways to announce first quarter financial results on May 8, 2024
|
May 2 |
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
|
Apr 29 |
Psychedelic drug developers could benefit from NIH funding for chronic pain
|
Apr 29 |
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
|
Apr 25 |
COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
|